Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Wrap Technologies, Golar LNG, BioMarin Pharmaceuticals, and Garrett Motion and Encourages Investors to Contact the Firm
October 28, 2020 17:00 ET
|
Bragar Eagel & Squire
NEW YORK, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
DEADLINE ALERT for WRTC, GLNG, GTX, GTXMQ, and BMRN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
October 27, 2020 12:00 ET
|
The Law Offices of Frank R. Cruz
LOS ANGELES, Oct. 27, 2020 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GoHealth, Wrap Technologies, Golar LNG, and BioMarin Pharmaceuticals and Encourages Investors to Contact the Firm
October 21, 2020 17:00 ET
|
Bragar Eagel & Squire
NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Golar LNG, BioMarin Pharmaceuticals, Garrett Motion, and Peabody Energy and Encourages Investors to Contact the Firm
October 14, 2020 18:00 ET
|
Bragar Eagel & Squire
NEW YORK, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Wrap Technologies, Golar LNG, BioMarin Pharmaceuticals, and Garrett Motion and Encourages Investors to Contact the Firm
October 07, 2020 20:00 ET
|
Bragar Eagel & Squire
NEW YORK, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
BMRN STOCK ALERT: Zhang Investor Law Announces Securities Class Action Lawsuit Against BioMarin Pharmaceutical Inc. – BMRN
October 06, 2020 12:47 ET
|
Zhang Investor Law P.C.
NEW YORK, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between...
BIOMARIN ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against BioMarin Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
September 29, 2020 18:00 ET
|
Bragar Eagel & Squire
NEW YORK, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United...
BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia
December 12, 2016 08:29 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has initiated a global Phase 3 study for vosoritide, an analog of...
BioMarin Announces Third Quarter 2016 Financial Results
October 27, 2016 16:03 ET
|
BioMarin Pharmaceutical Inc.
- Third Quarter 2016 Total BioMarin Revenues Increase 34% Year over Year to $280 million - Vimizim Net Product Revenues Increase 25% Year over Year to $81 million in the Third Quarter 2016 - Kuvan...
BioMarin Presents Vosoritide Data in Achondroplasia at American Society of Human Genetics (ASHG) 2016 Meeting
October 19, 2016 17:01 ET
|
BioMarin Pharmaceutical Inc.
Highest Dose (30 µg/kg/day) Shows Approximately 50% Increase in Mean Annualized Growth Velocity, Comparable with 15 µg/kg/day dose Consistent Safety Profile at High Dose Findings Support 15...